Giuseppe Curigliano

Summary

Affiliation: European Institute of Oncology
Country: Italy

Publications

  1. ncbi request reprint Diagnosis of T1 bladder transitional cell carcinoma by denaturing gradient gel electrophoresis urinalysis
    G Curigliano
    European Institute of Oncology, Division of Medical Oncology, Milano, Italy
    Anticancer Res 21:3015-20. 2001
  2. doi request reprint Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy
    Carmen Criscitiello
    Istituto Europeo di Oncologia, Division of Early Drug Development for Innovative Therapies, Via Ripamonti 435, 20133 Milano, Italy 39 02 57489788 39 02 57489581
    Expert Opin Investig Drugs 23:599-610. 2014
  3. doi request reprint Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium
    Giuseppe Curigliano
    Early Drug Development for Innovative Therapies Division, European Institute of Oncology, Via Ripamonti 435, 20141 Milano, Italy Electronic address
    Breast 22:S96-9. 2013
  4. doi request reprint Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer
    Giuseppe Curigliano
    Early Drug Development for Innovative Therapies Division, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141, Milano, Italy Electronic address
    Breast 22:650-6. 2013
  5. doi request reprint New drugs for breast cancer subtypes: targeting driver pathways to overcome resistance
    Giuseppe Curigliano
    Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Cancer Treat Rev 38:303-10. 2012
  6. ncbi request reprint Breast cancer vaccines: a clinical reality or fairy tale?
    G Curigliano
    Department of Medicine, Clinical Pharmacology and New Drugs Development Unit, Division of Experimental Oncology, Laboratory of Experimental Immunology, European Institute of Oncology, Milan, Italy
    Ann Oncol 17:750-62. 2006
  7. doi request reprint Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer
    Giuseppe Curigliano
    Department of Medicine, Division of Medical Oncology, Istituto Europeo di Oncologia, Milano, Italy
    J Clin Oncol 27:5693-9. 2009
  8. ncbi request reprint Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib
    Giuseppe Curigliano
    Division of Medical Oncology, Clinical Pharmacology and New Drugs Development Unit, European Institute of Oncology and University of Milan School of Medicine, Milano, Italy
    Prostate 67:603-4. 2007
  9. ncbi request reprint Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity
    Giuseppe Curigliano
    Division of Medical Oncology, Clinical Pharmacology and New Drugs Development Unit, European Institute of Oncology, Milan, Italy
    Anticancer Drugs 18:949-54. 2007
  10. ncbi request reprint Immunology and breast cancer: therapeutic cancer vaccines
    Giuseppe Curigliano
    Department of Medicine, Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milano, Italy
    Breast 16:S20-6. 2007

Detail Information

Publications98

  1. ncbi request reprint Diagnosis of T1 bladder transitional cell carcinoma by denaturing gradient gel electrophoresis urinalysis
    G Curigliano
    European Institute of Oncology, Division of Medical Oncology, Milano, Italy
    Anticancer Res 21:3015-20. 2001
    ..The diagnosis and follow-up of patients with T1 bladder cancer relies invasive procedures. We developed a non-invasive method for detection of T1 bladder cancer based on a feasible non-radioactive molecular approach...
  2. doi request reprint Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy
    Carmen Criscitiello
    Istituto Europeo di Oncologia, Division of Early Drug Development for Innovative Therapies, Via Ripamonti 435, 20133 Milano, Italy 39 02 57489788 39 02 57489581
    Expert Opin Investig Drugs 23:599-610. 2014
    ..More selective PDGFR inhibitors with reduced side effects will be crucial for combinatorial therapies. Development of sensitive diagnostics is of critical importance for patient selection and monitoring of therapeutic effects. ..
  3. doi request reprint Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium
    Giuseppe Curigliano
    Early Drug Development for Innovative Therapies Division, European Institute of Oncology, Via Ripamonti 435, 20141 Milano, Italy Electronic address
    Breast 22:S96-9. 2013
    ..Modulation of immune response in cancer patients is the result of a balanced activity of T regulators and T effector cells...
  4. doi request reprint Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer
    Giuseppe Curigliano
    Early Drug Development for Innovative Therapies Division, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141, Milano, Italy Electronic address
    Breast 22:650-6. 2013
    ..This randomized, open-label phase II study compared the efficacy of sunitinib monotherapy with that of single-agent standard-of-care (SOC) chemotherapy in patients with previously treated advanced triple-negative breast cancer (TNBC)...
  5. doi request reprint New drugs for breast cancer subtypes: targeting driver pathways to overcome resistance
    Giuseppe Curigliano
    Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Cancer Treat Rev 38:303-10. 2012
    ..We will review all new emerging agents targeting the driver pathways within breast cancer molecular subtypes...
  6. ncbi request reprint Breast cancer vaccines: a clinical reality or fairy tale?
    G Curigliano
    Department of Medicine, Clinical Pharmacology and New Drugs Development Unit, Division of Experimental Oncology, Laboratory of Experimental Immunology, European Institute of Oncology, Milan, Italy
    Ann Oncol 17:750-62. 2006
    ..The review discusses possible future directions for vaccine development and applications in the adjuvant setting...
  7. doi request reprint Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer
    Giuseppe Curigliano
    Department of Medicine, Division of Medical Oncology, Istituto Europeo di Oncologia, Milano, Italy
    J Clin Oncol 27:5693-9. 2009
    ..To assess the prognostic role of HER2 overexpression/amplification in patients with node-negative, pT1a-b breast cancers...
  8. ncbi request reprint Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib
    Giuseppe Curigliano
    Division of Medical Oncology, Clinical Pharmacology and New Drugs Development Unit, European Institute of Oncology and University of Milan School of Medicine, Milano, Italy
    Prostate 67:603-4. 2007
    ..To our knowledge no data have been reported on EGFR gene mutations in hormone refractory prostate cancer (HRPC)...
  9. ncbi request reprint Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity
    Giuseppe Curigliano
    Division of Medical Oncology, Clinical Pharmacology and New Drugs Development Unit, European Institute of Oncology, Milan, Italy
    Anticancer Drugs 18:949-54. 2007
    ..The study was discontinued before target accrual was reached owing to lack of efficacy of the drug. Our results do not support the efficacy of gefitinib in combination with endocrine treatment for hormone-refractory prostate cancer...
  10. ncbi request reprint Immunology and breast cancer: therapeutic cancer vaccines
    Giuseppe Curigliano
    Department of Medicine, Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milano, Italy
    Breast 16:S20-6. 2007
    ....
  11. ncbi request reprint Vaccine immunotherapy in breast cancer treatment: promising, but still early
    Giuseppe Curigliano
    European Institute of Oncology, Department of Medicine, Division of Medical Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Expert Rev Anticancer Ther 7:1225-41. 2007
    ..Another focus of the review is to provide the reader with future challenges in the field, taking into account both the immunological and clinical aspects to better target the goal...
  12. ncbi request reprint Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development
    Giuseppe Curigliano
    Division of Medical Oncology, Clinical Pharmacology and New Drugs Development Unit, European Institute of Oncology, Via Ripamonti 435, 20141 Milano, Italy
    Eur J Cancer 44:494-500. 2008
    ....
  13. doi request reprint Immunizing against breast cancer: a new swing for an old sword
    Giuseppe Curigliano
    European Institute of Oncology, Department of Medicine, Division of Medical Oncology, Via Ripamonti 435, Milan, Italy
    Breast 18:S51-4. 2009
    ....
  14. ncbi request reprint Cisplatin, etoposide and continuous infusion bleomycin in patients with testicular germ cell tumors: efficacy and toxicity data from a retrospective study
    G Curigliano
    Division of Medical Oncology, Universita di Milano, Milan, Italy
    J Chemother 21:687-92. 2009
    ..The main limitations of our study are related to the retrospective analysis, the limited number of patients and the restricted follow-up time. A prolonged follow-up is necessary to evaluate long term toxicity and outcome...
  15. doi request reprint Cancer-testis antigen expression in triple-negative breast cancer
    G Curigliano
    Department of Medicine, Division of Medical Oncology, Milano, Italy
    Ann Oncol 22:98-103. 2011
    ..The aim of this study was to investigate the expression of CT antigens in breast cancer...
  16. doi request reprint Cardiac toxicity from systemic cancer therapy: a comprehensive review
    Giuseppe Curigliano
    Division of Medical Oncology, Department of Medicine, Istituto Europeo di Oncologia, Miano, Italy
    Prog Cardiovasc Dis 53:94-104. 2010
    ..The aim of this review is to summarize potential cardiovascular toxicities for a range of cancer chemotherapeutics and to review general mechanisms of cardiovascular toxicity for each agent...
  17. doi request reprint Should liver metastases of breast cancer be biopsied to improve treatment choice?
    G Curigliano
    Department of Medicine, Division of Medical Oncology, Istituto Europeo di Oncologia, Milan, Italy
    Ann Oncol 22:2227-33. 2011
    ....
  18. doi request reprint The triple-negative subtype: new ideas for the poorest prognosis breast cancer
    Giuseppe Curigliano
    Department of Medicine, Division of Medical Oncology, Istituto Europeo di Oncologia, Milano 20141, Italy
    J Natl Cancer Inst Monogr 2011:108-10. 2011
    ..Chemotherapy is a cornerstone of current clinical practice for this type of disease. Progress might derive from refined biology-driven phase II trials that will also integrate targeted agents with chemotherapy...
  19. doi request reprint Targeting the subtypes of breast cancer: rethinking investigational drugs
    Giuseppe Curigliano
    Division of Medical Oncology, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141 Milano, Italia
    Expert Opin Investig Drugs 21:191-204. 2012
    ..Questions raised during the decision process include the following: i) What leads to the use of endocrine therapy? ii) What leads to the use of anti-HER2 therapy? iii) What justifies the use of chemotherapy?..
  20. ncbi request reprint Adjuvant therapy for very young women with breast cancer: response according to biologic and endocrine features
    Giuseppe Curigliano
    European Institute of Oncology, Milan, Italy
    Clin Breast Cancer 5:125-30. 2004
    ..The development of more effective therapies for very young women with breast cancer requires tailored treatment investigations and research focused on issues specific to these patients...
  21. ncbi request reprint Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay
    G Curigliano
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 13:895-902. 2002
    ..No studies exist on the role of these factors in male breast carcinoma...
  22. ncbi request reprint GSTM1, P53 and K-ras molecular detection in resectable non-small cell lung cancer by denaturing gradient gel electrophoresis-bronchoalveolar lavage fluid analysis
    G Curigliano
    European Institute of Oncology, Department of Medicine, Milano, Italy
    Anticancer Res 21:3461-9. 2001
    ..These might include the identification of patients at high risk for primary NSCLC and the surveillance of patients with known NSCLC who are being treated using lung-sparing surgical strategies...
  23. doi request reprint Immunity and autoimmunity: revising the concepts of response to breast cancer
    Giuseppe Curigliano
    Department of Medicine, Division of Medical Oncology, Istituto Europeo di Oncologia, Milano, Italy
    Breast 20:S71-4. 2011
    ..The identification of immunological and genetic features affecting immune response in patients with minimal tumor burden are the optimal background for development of clinical studies in the adjuvant setting...
  24. ncbi request reprint A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer
    Andrea Rocca
    Unit of Research in Medical Senology, Department of Medicine, Division of Pathology, University of Milan School of Medicine, Italy
    Anticancer Drugs 17:1201-9. 2006
    ..Perioperative chemotherapy failed to show an increase in the pathological complete remission rate. A biological effect on Ki-67 expression was demonstrated...
  25. ncbi request reprint Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare
    Tommaso De Pas
    Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    J Clin Oncol 22:4966-70. 2004
    ....
  26. ncbi request reprint Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients
    Roberto Gennari
    Department of Surgery, European Institute of Oncology, Milan, Italy
    Cancer 101:1302-10. 2004
    ..The aim of the study was to evaluate the relation between biologic features at first diagnosis of breast carcinoma and treatment choice for postmenopausal women > or = 50 years to optimize treatment in the elderly...
  27. doi request reprint Health-related quality of life in patients with hormone refractory prostate cancer receiving gefitinib
    Giuseppe Curigliano
    Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    Urol Int 82:196-202. 2009
    ..Improvements in quality of life (QoL) and disease-related symptoms are key goals in the treatment of hormone refractory prostate cancer (HRPC). Our aim was to evaluate the impact of gefitinib on QoL of patients with HRPC...
  28. doi request reprint Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer
    Elisabetta Munzone
    Division of Medical Oncology, Istituto Europeo di Oncologia, Milan, Italy
    Clin Breast Cancer 12:340-6. 2012
    ..Breast cancer is a heterogeneous disease. Circulating tumor cell (CTC) enumeration might be useful to identify different risk categories within each molecular subtype...
  29. pmc Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
    Elisabetta Munzone
    Department of Medicine, Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast Cancer Res 8:R4. 2006
    ..These sequences of events indicate that a phenotype based on ER expression may not be a permanent feature of breast cancer...
  30. doi request reprint Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer
    Edoardo Botteri
    Division of Epidemiology and Biostatistics, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast Cancer Res Treat 122:211-7. 2010
    ..If distinct prognostic groups are to be identified, women with no CTC could plausibly represent a distinct favorable one...
  31. doi request reprint A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases
    Gaetano Aurilio
    European Institute of Oncology, Medical Oncology, Via Ripamonti 435, Milan, Italy Electronic address
    Eur J Cancer 50:277-89. 2014
    ..However, results from different studies are heterogeneous and often conflicting. To highlight this issue, a meta-analysis of published data was performed...
  32. doi request reprint Risk of locoregional recurrence in patients with false-negative frozen section or close margins of retroareolar specimen in nipple-sparing mastectomy
    Maximiliano Cassilha Kneubil
    Division of Plastic Reconstruction Surgery, European Institute of Oncology, Milan, Italy
    Ann Surg Oncol 19:4117-23. 2012
    ..Our purpose was to evaluate the locoregional recurrence (LRR) of patients with false-negative, frozen-section or close margins of retroareolar specimen in nipple-sparing mastectomy (NSM) procedure...
  33. doi request reprint Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report
    Gaetano Aurilio
    European Institute of Oncology, Medical Oncology, Milan, Italy
    Breast J 18:470-4. 2012
    ..The prolonged clinical benefit, often desirable in such patients, supports this regimen as an additional and useful therapeutic tool...
  34. doi request reprint Biopsy of liver metastasis for women with breast cancer: impact on survival
    Edoardo Botteri
    Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
    Breast 21:284-8. 2012
    ..Biopsy of metastatic site of disease can influence treatment decisions, but its impact on survival remains uncertain...
  35. ncbi request reprint Optimization of the schedule of gemcitabine-cisplatin combination as induction regimen for patients with biopsy-proven stage IIIa N2 - stage IIIb non-small-cell lung cancer: a prospective phase-II study
    Tommaso De Pas
    Department of Medical Oncology, Division of Thoracic Surgery and Radiotherapy, European Institute of Oncology, Via Ripamonti, 435, 20141, Milan, Italy
    Bull Cancer 91:E273-7. 2004
    ..When given as induction chemotherapy, a three-week schedule of CDDP plus GCB combination appeared to be effective, with lower toxicity and better compliance than a four-week schedule...
  36. ncbi request reprint Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter
    Giuseppe Curigliano
    Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Support Care Cancer 15:1213-7. 2007
    ..The aim of this study was to evaluate the efficacy and safety of low-dose aspirin for the prevention of VTE...
  37. ncbi request reprint Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment
    Marco Colleoni
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Clin Cancer Res 10:6622-8. 2004
    ..The purpose of this research was to identify factors predicting response to preoperative chemotherapy...
  38. doi request reprint Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients
    Luca Mazzarella
    Division of Medical Oncology, Istituto Europeo di Oncologia, Milan, Italy Department of Experimental Oncology, Istituto Europeo di Oncologia, Milan, Italy Electronic address
    Eur J Cancer 49:3588-97. 2013
    ..However, there are contrasting data on the differential impact of obesity on specific breast cancer subtypes. In particular, very little is known on human epidermal growth factor receptor 2-positive (HER2+) tumours...
  39. doi request reprint High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer
    Carmen Criscitiello
    Early Drug Development for Innovative Therapies Division, Department of Medicine, European Institute of Oncology, Milan, Italy
    Breast 23:69-75. 2014
    ..We analyzed the predictive value of Ki67 for the efficacy of adjuvant chemotherapy in patients with estrogen receptor-positive, node-positive breast cancer...
  40. doi request reprint Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer
    Elisabetta Munzone
    Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    Clin Breast Cancer 10:392-7. 2010
    ..HER2/neu status of tumor cells at metastatic sites in patients with advanced disease may differ from that of the primary tumor. Assessing the presence of target antigens on circulating tumor cells (CTCs) might affect treatment choice...
  41. doi request reprint Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials
    Janaina Brollo
    Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Cancer Treat Rev 39:44-50. 2013
    ..Acute and chronic medical conditions, nutritional status and level of daily activities should be considered. Uncertainty about cardiac safety in the elderly is a major concern...
  42. ncbi request reprint Factor v leiden mutation in patients with breast cancer with a central venous catheter: risk of deep vein thrombosis
    Giuseppe Curigliano
    Division of Medical Oncology, Clinical Pharmacology and New Drugs Development Unit, European Institute of Oncology, Milan, Italy
    Support Cancer Ther 3:98-102. 2006
    ..Clinicians should be aware of this increased risk, and alternative cytotoxic treatments not requiring continuous infusions should be considered for these patients...
  43. ncbi request reprint Intrathecal chemotherapy in carcinomatous meningitis from breast cancer
    Laura Orlando
    Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Anticancer Res 22:3057-9. 2002
    ..We therefore evaluated the efficacy of an ITC regimen for patients presenting with carcinomatous meningitis from breast cancer...
  44. doi request reprint Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer
    Gaetano Aurilio
    Medical Oncology, European Institute of Oncology, Milan, Italy
    Acta Oncol 52:1649-56. 2013
    ....
  45. doi request reprint Locoregional recurrence in patients with HER2 positive breast cancer
    Janaina Brollo
    Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Breast 22:856-62. 2013
    ..Moreover, we underline the importance of PgR and further new stratification of risk among luminal subtypes...
  46. ncbi request reprint Venous thromboembolism and cancer: new issues for an old topic
    Mario Mandala
    Division of Medical Oncology, Treviglio Hospital, P le Ospedale 1, 24047 Treviglio, Italy
    Crit Rev Oncol Hematol 48:65-80. 2003
    ..Better knowledge about the biochemical bases of the coagulation process represents a pivotal step in cancer biology comprehension and global therapeutic management...
  47. ncbi request reprint Vinorelbine-based chemotherapy in hormone-refractory prostate cancer
    M G Zampino
    Department of Medicine, European Institute of Oncology, 20141 Milan, Italy
    Anticancer Res 26:2375-80. 2006
    ..In this phase II study, the combination of Vinorelbine with 5-Fluorouracil and folinic acid (FLN regimen) was evaluated in patients with progressive or resistant disease after hormone therapy...
  48. doi request reprint Nipple-sparing mastectomy--is it worth the risk?
    Jean Yves Petit
    Division of Plastic Surgery, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Nat Rev Clin Oncol 8:742-7. 2011
    ....
  49. doi request reprint Safety, tolerability and biological effects of long-term metronomic administration of non-cytotoxic anti-angiogenic agents
    Cristina Noberasco
    Clinical Pharmacology and New Drugs Development Unit, Department of Medicine, European Institute of Oncology, Milan, Italy
    Oncology 77:358-65. 2009
    ..alpha-Interferon, thalidomide and celecoxib inhibit tumour angiogenesis by differing mechanisms...
  50. ncbi request reprint Dendritic cell sarcoma: an analytic overview of the literature and presentation of original five cases
    Tommaso De Pas
    New Drugs Development and Clinical Pharmacology Unit, Department of Medicine, European Institute of Oncology, Milan, Italy
    Crit Rev Oncol Hematol 65:1-7. 2008
    ..Both the analytic revision of the literature and our data suggest that localized DCS may be effectively treated by radical surgery and do not support the use of adjuvant treatments after radical excision...
  51. doi request reprint The management of ductal intraepithelial neoplasia (DIN): open controversies and guidelines of the Istituto Europeo di Oncologia (IEO), Milan, Italy
    Gabriel Farante
    Division of Senology, European Institute of Oncology, IEO, Via Ripamonti 435, 20141 Milan, Italy
    Breast Cancer Res Treat 128:369-78. 2011
    ..A general agreement on the best management of DIN does not exist as yet. New large trials are needed in order to define the best management of DIN patients which is (in most respects) still complex and controversial...
  52. doi request reprint End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for Clinical Trials in Oncology--International Society Of Geriatric Oncology position article
    Hans Wildiers
    Hans Wildiers, Murielle Mauer, Athanasios Pallis, Andrea Luciani, Giuseppe Curigliano, Martine Extermann, and Ulrich Wedding, European Organisation for Research and Treatment of Cancer, Brussels Hans Wildiers, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven, Belgium Hans Wildiers, Arti Hurria, Harvey Jay Cohen, and Ulrich Wedding, International Society of Geriatric Oncology, Geneva, Switzerland Arti Hurria, City of Hope, Duarte, CA Arti Hurria, Karla Ballman, Harvey Jay Cohen, and Hyman Muss, Alliance, Chicago, IL Supriya G Mohile, University of Rochester, Rochester Stuart M Lichtman, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY Andrea Luciani, S Paolo Hospital Giuseppe Curigliano, European Institute of Oncology, Milano, Italy Martine Extermann
    J Clin Oncol 31:3711-8. 2013
    ....
  53. ncbi request reprint Challenges and prospects of immunotherapy as cancer treatment
    Maria Rescigno
    Department of Experimental Oncology, European Institute of Oncology, Via Ripamonti, 435, 20141, Milan, Italy
    Biochim Biophys Acta 1776:108-23. 2007
    ....
  54. doi request reprint Tailoring adjuvant treatments for the individual patient with luminal breast cancer
    Elisabetta Munzone
    Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, Milan 20141, Italy
    Hematol Oncol Clin North Am 27:703-14, vii-viii. 2013
    ..Controversies still exist on the identification of those patients who do not benefit from chemotherapy. Tailored adjuvant treatments should be considered in the therapeutic algorithm of patients with luminal tumors. ..
  55. doi request reprint Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander"
    Lucia Gelao
    Division of Early Drug Development for Innovative Therapies, Istituto Europeo di Oncologia, Via Ripamonti 435, Milano 20141, Italy
    Toxins (Basel) 6:914-33. 2014
    ..Third, rigorous biomarker-driven clinical trials are needed to further elucidate the mechanisms of both the benefit and toxicity. We will summarize the double-edged sword effect of immunotherapeutics in cancer treatment. ..
  56. doi request reprint No link between breast cancer and meningioma: results from a large monoinstitutional retrospective analysis
    Carmen Criscitiello
    Authors Affiliations Breast Cancer Program, Division of Early Drug Development, Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan and Department of Advanced Biomedical Sciences, Operative Unit of General Surgery and Transplants, University Naples Federico II, Napoli, Italy
    Cancer Epidemiol Biomarkers Prev 23:215-7. 2014
    ..The etiology of meningioma is largely unknown, although breast cancer has been suggested to play a role...
  57. ncbi request reprint Catheter-related bloodstream infections, part II: specific pathogens and prevention
    Gianluigi Ferretti
    Division of Medical Oncology, Treviglio Hospital, Italy
    Cancer Control 10:79-91. 2003
  58. doi request reprint Autologous fat transplantation in patients with breast cancer: "silencing" or "fueling" cancer recurrence?
    Visnu Lohsiriwat
    Division of Reconstructive Surgery, European Institute of Oncology, Milan, Italy
    Breast 20:351-7. 2011
    ..To confirm the safety of lipotransfer in breast cancer patients we need clinical studies with control group based on long term follow up...
  59. ncbi request reprint A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients
    Tommaso De Pas
    New Drugs Development Unit, Italy
    Lung Cancer 54:359-64. 2006
    ..The dose of GEM 1500 mg/m(2) and TAX 100 mg/m(2) was selected for phase II studies due to its predictable kinetic behaviour and less severe thrombocytopenia...
  60. ncbi request reprint Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients
    M Mandala
    Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Anticancer Res 21:585-8. 2001
    ..The present investigation was performed to evaluate the effect of acute and chronic tamoxifen administration on GH response to growth hormone-releasing hormone (GHRH), as well as on IGF-1 serum levels...
  61. ncbi request reprint Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors
    M Colleoni
    Division of Medical Oncology, Istituto Europeo di Oncologia, Milan, Italy
    Ann Oncol 11:1057-9. 2000
    ..To test this hypothesis we evaluated the responsiveness to preoperative chemotherapy in patients with ER and progesterone receptors (PgR)-absent tumors...
  62. ncbi request reprint Hepatic intra-arterial chemotherapy using a percutaneous catheter in pretreated patients with metastatic colorectal carcinoma
    N Fazio
    Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Anticancer Res 23:5023-30. 2003
    ..The aim of this study was to evaluate the activity and safety of giving HIAC through a percutaneous catheter in pre-treated patients...
  63. ncbi request reprint Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer
    T De Pas
    Division of Medical Oncology, European Institute of Oncology, Milano, Italy
    Ann Oncol 11:821-7. 2000
    ..We performed a phase I study to determine the maximum-tolerated dose (MTD), antitumor activity and pharmacokinetics of GEM and TAX given weekly in chemo-naïve patients with advanced NSCLC...
  64. ncbi request reprint Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer
    G Ferretti
    Division of Medical Oncology, European Institute of Oncology, Milano, Italy
    Clin Cancer Res 6:2393-400. 2000
    ..8% test accuracy. The method proposed demonstrated to be specific, accurate, and at relatively low cost but limited by low sensitivity in detecting the presence of neoplastic cells in patients with resectable non-small cell lung cancer...
  65. ncbi request reprint Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine
    T De Pas
    Divisions of Medical Oncology, European Institute of Oncology, Via Ripamonti, 435, 20141 Milan, Italy
    Lung Cancer 31:267-70. 2001
    ..We recommend the use of this regimen for patients not refractory to primary treatment...
  66. ncbi request reprint Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas
    T De Pas
    Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    Ann Oncol 13:161-6. 2002
    ....
  67. ncbi request reprint Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanced breast cancer: a promising low-toxic regimen
    L Orlando
    Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    Anticancer Res 21:4135-9. 2001
    ....
  68. pmc Imatinib administration in two patients with liver metastases from GIST and severe jaundice
    T De Pas
    Department of Medical Oncology, European Institute of Oncology, Via Ripamonti, 435, Milano 20141, Italy
    Br J Cancer 89:1403-4. 2003
    ..We provide evidence that imatinib tolerability was not adversely affected by jaundice in two patients with advanced GIST...
  69. ncbi request reprint Oral administration of vinorelbine can overcome intractable endovenous-vinorelbine-associated acute tumor pain
    T De Pas
    Department of Medical Oncology, European Institute of Oncology, Milan, Italy
    Support Care Cancer 13:194-5. 2005
  70. ncbi request reprint Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase
    M Colleoni
    Department of Medicine, University of Milan School of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 14:1477-83. 2003
    ....
  71. ncbi request reprint Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype
    L Orlando
    Division of Medical Oncology, Department of Medicine, Division of Pathology and Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
    Ann Oncol 16:1094-9. 2005
    ..We retrospectively evaluated the clinical relevance of selected immunohistochemical features of tumors in three cohorts of patients with typical medullary (MC), 'atypical' medullary (AMC) or ductal (DC) breast carcinoma...
  72. ncbi request reprint Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), Vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or exten
    G Curigliano
    Department of Medicine, Division of Medical Oncology, Clinical Pharmacology and New Drugs Development Unit, European Institute of Oncology, Via Ripamonti 435, 20141 Milano, Italy
    Breast Cancer Res Treat 93:35-40. 2005
    ..To assess if feature, extent and duration of surgery could influence levels of systemic proangiogenic cytokines vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and transforming growth factor beta (TGF-beta)...
  73. ncbi request reprint Preoperative chemotherapy is essential for conservative surgery of Askin tumors
    G Veronesi
    Thoracic Surgery Division, European Institute of Oncology, Milan, Italy
    J Thorac Cardiovasc Surg 125:428-9. 2003
  74. doi request reprint Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer
    G Spitaleri
    Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    Ann Oncol 20:498-502. 2009
    ..We carried out a phase II trial to determine the activity and safety of estramustine plus oral etoposide in HRPC...
  75. ncbi request reprint Gemcitabine-induced systemic capillary leak syndrome
    T De Pas
    Division of Medical Oncology, European Institute of Oncology, Milano, Italy
    Ann Oncol 12:1651-2. 2001
    ..This finding can help to better understand and treat the potentially deadly GCB-related acute respiratory distress syndrome that is being recognized...
  76. doi request reprint Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report
    E Munzone
    Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, Milan, Italy
    Breast 19:33-7. 2010
    ..Pegylated liposomal-doxorubicin (PLD) pharmacokinetic characteristics support the rationale for using the drug in a metronomic fashion, potentially able to combine anthracyclines efficacy to a low toxicity profile...
  77. doi request reprint Molecular pathways: human leukocyte antigen G (HLA-G)
    Giuseppe Curigliano
    Authors Affiliation Division of Early Drug Development for Innovative Therapies, Istituto Europeo di Oncologia, Milan, Italy
    Clin Cancer Res 19:5564-71. 2013
    ..As HLA-G is a potent immunoinhibitory molecule, its blockade remains an attractive therapeutic strategy against cancer. Elimination of HLA-G-expressing cancer cells would be important in the efficacy of anticancer therapies...
  78. doi request reprint Coagulation disorders in patients with cancer: nontunneled central venous catheter placement with US guidance--a single-institution retrospective analysis
    Paolo Della Vigna
    Division of Radiology, Interventional Radiology Unit, Department of Medicine, European Institute of Oncology, 20141 Milan, Italy
    Radiology 253:249-52. 2009
    ..To assess the feasibility and safety of ultrasonographic (US) guidance in the placement of nontunneled central venous catheters (CVCs) in patients with cancer who had altered coagulation profiles...
  79. doi request reprint Systemic therapies for non-metastatic prostate cancer: review of the literature
    Barbara Alicja Jereczek-Fossa
    Dept of Radiation Oncology, Division of Medical Oncology of the European Institute of Oncology, University of Milan, Milan, Italy
    Onkologie 32:359-63. 2009
    ..The ongoing trials will hopefully further define the role of systemic therapies in prostate cancer and explore the less toxic agents/combinations in order to improve the treatment outcome without excessive side effects...
  80. ncbi request reprint Male breast cancer: a special therapeutic problem. Anything new? (Review)
    Roberto Gennari
    Department of Surgery, European Institute of Oncology, 20141 Milano, Italy
    Int J Oncol 24:663-70. 2004
    ....
  81. pmc Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up?
    Giuseppe Curigliano
    Division of Early Drug Development, European Institute of Oncology, Milan, Italy
    Ecancermedicalscience 7:299. 2013
    ..The final goal will be to improve access to an affordable, best standard of care for all patients in each country...
  82. ncbi request reprint Impact of limited pulmonary function on the management of resectable lung cancer
    Piergiorgio Solli
    Division of Thoracic Surgery, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Lung Cancer 41:71-9. 2003
    ..Purpose of this study was to investigate the frequency of LPF in lung cancer and its impact of on surgical eligibility and postoperative outcome...
  83. ncbi request reprint Postoperative hyperprolactinemia could predict longer disease-free and overall survival in node-negative breast cancer patients
    Mario Mandala
    Division of Medical Oncology, Treviglio Hospital, Italy
    Oncology 63:370-7. 2002
    ..Surgery-induced hyperprolactinemia may be associated with a longer disease-free survival in both patients with or without node involvement...
  84. doi request reprint Immunotherapeutics for breast cancer
    Carmen Criscitiello
    Division of Early Drug Development for Innovative Therapies, Istituto Europeo di Oncologia, Milan, Italy
    Curr Opin Oncol 25:602-8. 2013
    ..We review recent advances leading to a new understanding of immunology of breast cancer with its potential clinical applications...
  85. doi request reprint HER2 signaling pathway and trastuzumab cardiotoxicity
    Carmen Criscitiello
    Division of Medical Oncology, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141 Milan, Italy
    Future Oncol 9:179-81. 2013
    ..In the era of personalized medicine, efforts are needed to promote strategies for risk detection and management to avoid dangerous toxicities that may impede the development of and patient access to new agents...
  86. ncbi request reprint Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter
    M Mandala
    Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    Ann Oncol 15:590-3. 2004
    ....
  87. ncbi request reprint Ifosfamide in the elderly: clinical considerations for a better drug management
    T De Pas
    Department of Medical Oncology, European Institute of Oncology, Milan, Italy
    Crit Rev Oncol Hematol 33:129-35. 2000
    ..Finally, we propose clinical guidelines to optimize the use of ifosfamide in elderly patients affected by malignant tumors...
  88. ncbi request reprint Immunohistochemical detection of HER1/HER2 can be considered a predictive marker of gefitinib activity in non-small-cell lung cancer?
    Cristina Noberasco
    J Clin Oncol 23:921-2; author reply 922. 2005
  89. ncbi request reprint Preoperative chemotherapy in non-small-cell lung cancer: nothing new in N2 disease
    Tommaso De Pas
    J Clin Oncol 20:2603-4; author reply 2605. 2002
  90. ncbi request reprint Target-treatment and patients' selection: can we still neglect the timing of tissue collection?
    Tommaso De Pas
    J Clin Oncol 23:6274-5; author reply 6275-6. 2005
  91. ncbi request reprint Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer
    Filippo De Braud
    J Natl Cancer Inst 97:461-2; author reply 462-3. 2005
  92. ncbi request reprint Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer
    Romano Danesi
    Division of Pharmacology and Chemotherapy, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Pisa, Italy
    Pharmacol Rev 55:57-103. 2003
    ....
  93. ncbi request reprint Treatment of rectal cancer
    Giuseppe Curigliano
    N Engl J Med 355:2487; author reply 2487-8. 2006
  94. ncbi request reprint Re: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non small-cell lung cancer
    Francesco Leo
    J Natl Cancer Inst 99:1210; author reply 1210-1. 2007
  95. ncbi request reprint Re: Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial
    Nicola Fazio
    J Natl Cancer Inst 99:1345-6; author reply 1346-7. 2007
  96. ncbi request reprint Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails
    Cristiana Sessa
    Southern Europe New Drugs Organization Foundation, Via Visconti di Modrone 12, 20100 Milano, Italy
    J Clin Oncol 23:1867-74. 2005
    ..To assess the efficacy and toxicity of the marine-derived alkaloid trabectedin (ET-743) in patients with advanced ovarian cancer refractory to or experiencing disease relapse after platinum- and taxane-based chemotherapy...
  97. ncbi request reprint Palliative home care and cost savings: encouraging results from Italy
    Serena Di Cosimo
    N Z Med J 116:U370. 2003
  98. ncbi request reprint Drug-induced prolongation of the QT interval
    Giuseppe Curigliano
    N Engl J Med 350:2618-21; author reply 2618-21. 2004